medigraphic.com
ISSN 2500-7106 (Digital)
ISSN 0123-2576 (Impreso)
Medicina & Laboratorio

2022, Número 1

<< Anterior

Medicina & Laboratorio 2022; 26 (1)


Índice de Salud Prostática (phi)

Toro-Montoya AI, Vizcaíno-Carruyo JC, Guevara-Arismendy NM, Campuzano-Zuluaga G

Idioma: Español
Referencias bibliográficas: 30
Paginas: 91-98
Archivo PDF: 206.00 Kb.


FRAGMENTO

Utilidad clínica de la prueba

En Colombia, el cáncer de próstata es una de las principales causas de mortalidad por cáncer, el cual se ha triplicado durante los últimos años, con una incidencia anual de 14.460 casos y una mortalidad de 3.846 durante el 2020.
El antígeno específico de próstata (PSA, del inglés, Prostate Specific Antigen) es una glicoproteína producida por la próstata, y es el marcador tumoral de mayor uso. Sin embargo, su baja especificidad para diferenciar entre cáncer de próstata y otras alteraciones no malignas, como la hipertrofia benigna de la próstata (HBP) y la prostatitis aguda, limitan su utilidad diagnóstica (figura 1). Se ha encontrado que los hombres con niveles de PSA entre 4 ng/mL y 10 ng/mL pueden tener un 30% a 35% de probabilidad de una biopsia positiva para carcinoma de próstata, y de manera alterna, del 15% al 30% de todos los casos de cáncer de próstata pueden tener un nivel de PSA por debajo de 4 ng/mL; además, su valor predictivo positivo relativamente bajo conlleva hasta un 70% de biopsias innecesarias .


REFERENCIAS (EN ESTE ARTÍCULO)

  1. World Health Organization (WHO). Incidence,mortality and prevalence by cancersite. The Global Cancer Observatory (GLOBOCAN); 2020. p. 1-2. Acceso 06 de abril de2021. Disponible en https://gco.iarc.fr/today/data/factsheets/populations/170-colombiafact-sheets.pdf.

  2. Carroll PR, Parsons JK, Andriole G, BahnsonRR, Castle EP, Catalona WJ, et al. NCCN GuidelinesInsights: Prostate Cancer Early Detection,Version 2.2016. J Natl Compr Canc Netw2016;14:509-519. https://doi.org/10.6004/jnccn.2016.0060.

  3. Thompson IM, Ankerst DP, Chi C, Lucia MS,Goodman PJ, Crowley JJ, et al. Operatingcharacteristics of prostate-specific antigenin men with an initial PSA level of 3.0 ng/mlor lower. JAMA 2005;294:66-70. https://doi.org/10.1001/jama.294.1.66.

  4. National Comprehensive Cancer Network(NCCN). NCCN Clinical Practice Guidelinesin Oncology: Prostate cancer early detection.Plymouth Meeting, USA: 2018. p. 1-52. Acceso02 de abril de 2021. Disponible en https://www2.tri-kobe.org/nccn/guideline/urological/english/prostate_detection.pdf.

  5. Vukovic I, Djordjevic D, Bojanic N, Babic U,Soldatovic I. Predictive value of [-2]proPSA(P2PSA) and its derivatives for the prostatecancer detection in the 2.0 to 10.0ng/mL PSArange. International Braz J Urol 2017;43:48-56. https://doi.org/10.1590/S1677-5538.IBJU.2016.0256.

  6. White J, Shenoy BV, Tutrone RF, Karsh LI,Saltzstein DR, Harmon WJ, et al. Clinical utilityof the Prostate Health Index (phi) for biopsydecision management in a large group urologypractice setting. Prostate Cancer ProstaticDis 2018;21:78-84. https://doi.org/10.1038/s41391-017-0008-7.

  7. Boegemann M, Stephan C, Cammann H, VincendeauS, Houlgatte A, Jung K, et al. Thepercentage of prostate-specific antigen (PSA)isoform [–2]proPSA and the Prostate HealthIndex improve the diagnostic accuracy for clinicallyrelevant prostate cancer at initial andrepeat biopsy compared with total PSA andpercentage free PSA in men aged ≤65 years.BJU International 2016;117:72-79. https://doi.org/10.1111/bju.13139.

  8. Jain S, Pincus MR, Bluth MH, McPherson RA,Bowne WB, Lee P. Diagnosis and managementof cancer using serologic and other body fluidmarkers. In: Pincus MR, Bluth MH, McPhersonRA, Bowne WB, eds. Henry´s Clinical Diagnosisand Management by Laboratory Methods. 23rded. St. Louis: Elsevier; 2017. p. 1442-1444.

  9. Algeciras-Schimnich A. Insights: The ProstateHealth Index (phi) in prostate cancer riskassessment. Minnesota, USA: Mayo Clinic Laboratories;2017. Department of LaboratoryMedicine and Pathology. Acceso 11 de mayode 2021. Disponible en https://news.mayocliniclabs.com/2017/08/14/prostate-health-indexphi-prostate-cancer-risk-assessment-hot-topic/.

  10. Özen H, Sözen S. PSA isoforms in prostate cancerdetection. Eur Urol Supp 2006;5:495-499.https://doi.org/10.1016/j.eursup.2006.02.017.

  11. Filella X, Foj L, Alcover J, Augé JM, EscuderoJM, Molina R. ProPSA, un nuevo biomarcadorpara la detección y el manejo del cáncer depróstata. Rev Laboratorio Clín 2013;6:75-81.https://doi.org/10.1016/j.labcli.2013.01.006.

  12. Mikolajczyk SD, Marker KM, Millar LS, KumarA, Saedi MS, Payne JK, et al. A truncatedprecursor form of prostate-specific antigen is amore specific serum marker of prostate cancer.Cancer Res 2001;61:6958-6963.

  13. U.S. Food & Drug Administration. Quantitativetest for determination of [-2]proPSA levels.Silver Spring: FDA Summary of Safety and EffectivenessData; 2012. p. 1-32. Acceso 15 de mayode 2021. Disponible en https://www.accessdata.fda.gov/cdrh_docs/pdf9/P090026b.pdf.

  14. Tosoian JJ, Druskin SC, Andreas D, MullaneP, Chappidi M, Joo S, et al. Use of the ProstateHealth Index for detection of prostate cancer:results from a large academic practice. ProstateCancer Prostatic Dis 2017;20:228-233. https://doi.org/10.1038/pcan.2016.72.

  15. Loeb S, Bruinsma SM, Nicholson J, BrigantiA, Pickles T, Kakehi Y, et al. Active surveillancefor prostate cancer: a systematic review ofclinicopathologic variables and biomarkers forrisk stratification. Eur Urol 2015;67:619-626.https://doi.org/10.1016/j.eururo.2014.10.010.

  16. de la Calle C, Patil D, Wei JT, Scherr DS,Sokoll L, Chan DW, et al. Multicenter evaluationof the Prostate Health Index to detectaggressive prostate cancer in biopsy naivemen. J Urol 2015;194:65-72. https://doi.org/10.1016/j.juro.2015.01.091.

  17. Osses DF, Remmers S, Schroder FH, van derKwast T, Roobol MJ. Results of prostate cancerscreening in a unique cohort at 19 yr of followup.Eur Urol 2019;75:374-377. https://doi.org/10.1016/j.eururo.2018.10.053.

  18. Abrate A, Lughezzani G, Gadda GM, Lista G,Kinzikeeva E, Fossati N, et al. Clinical use of[-2]proPSA (p2PSA) and its derivatives (%p2PSAand Prostate Health Index) for the detectionof prostate cancer: A review of the literature.Korean J Urol 2014;55:436-445. https://doi.org/10.4111/kju.2014.55.7.436.

  19. Heidegger I, Klocker H, Pichler R, PircherA, Prokop W, Steiner E, et al. ProPSA and theProstate Health Index as predictive markersfor aggressiveness in low-risk prostate cancerresultsfrom an international multicenter study.Prostate Cancer Prostatic Dis 2017;20:271-275.https://doi.org/10.1038/pcan.2017.3.

  20. Catalona WJ, Partin AW, Sanda MG, Wei JT,Klee GG, Bangma CH, et al. A multicenterstudy of [-2]pro-prostate specific antigen combinedwith prostate specific antigen and freeprostate specific antigen for prostate cancerdetection in the 2.0 to 10.0 ng/ml prostate specificantigen range. J Urol 2011;185:1650-1655.https://doi.org/10.1016/j.juro.2010.12.032.

  21. Shore ND, Pieczonka CM, Henderson RJ,Bailen JL, Saltzstein DR, Concepcion RS, etal. A comparison of prostate health index, totalPSA, %free PSA, and proPSA in a contemporaryUS population-The MiCheck-01 prospectivetrial. Urol Oncol 2020;38:683.e681-683.e610.https://doi.org/10.1016/j.urolonc.2020.03.011.

  22. Boegemann M, Arsov C, Hadaschik B,Herkommer K, Imkamp F, Nofer JR, et al.Discordant prostate specific antigen test resultsdespite WHO assay standardization. IntJ Biol Markers 2018;33:275-282. https://doi.org/10.1177/1724600818754750.

  23. Stephan C, Bangma C, Vignati G, BartschG, Lein M, Jung K, et al. 20-25% lower concentrationsof total and free prostate-specificantigen (PSA) after calibration of PSA assaysto the WHO reference materials--analysis of1098 patients in four centers. Int J Biol Markers2009;24:65-69.

  24. Vignati G, Giovanelli L. Standardization of PSAmeasures: a reappraisal and an experience withWHO calibration of Beckman Coulter AccessHybritech total and free PSA. Int J Biol Markers2007;22:295-301.

  25. Stephan C, Kopke T, Semjonow A, Lein M,Deger S, Schrader M, et al. Discordant totaland free prostate-specific antigen (PSA) assays:does calibration with WHO reference materialsdiminish the problem? Clin Chem Lab Med2009;47:1325-1331. https://doi.org/10.1515/CCLM.2009.285.

  26. Foj L, Filella X, Alcover J, Auge JM, EscuderoJM, Molina R. Variability of assay methods fortotal and free PSA after WHO standardization.Tumour Biol 2014;35:1867-1873. https://doi.org/10.1007/s13277-013-1249-2.

  27. Ferguson J, Atkinson E, Rigsby P, Burns C.WHO International Collaborative Study of theproposed 2nd WHO is for total PSA (PSA-ACT+ free PSA). Geneva, Switzerland: World HealthOrganization (WHO). Expert committee on biologicalstandardization; 2018. Acceso 03 deabril de 2021. Disponible en https://www.who.int/biologicals/BS.2018.2340_PSA_Total.pdf.

  28. Prostate Cancer UK. The test PSA. London, UK:Prostate Cancer UK; 2020. Acceso 19 de mayode 2021. Disponible en https://prostatecanceruk.org/prostate-information/prostate-tests/psa-test.

  29. Pagana KD, Pagana TJ. Mosby’s Manual ofDiagnostic and Laboratory Test. 4th ed. Misuri,USA; Mosby Elsevier; 2010.

  30. Bossens MM, Van Straalen JP, De Reijke TM,Kurth KH, Sanders GT. Kinetics of prostatespecificantigen after manipulation of the prostate.Eur J Cancer 1995;31a:682-685. https://doi.org/10.1016/0959-8049(95)00016-c.




2020     |     www.medigraphic.com